Ignite Creation Date:
2024-05-05 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 9:50 AM
Study NCT ID:
NCT00696917
Status:
COMPLETED
Last Update Posted:
2008-06-13
First Post:
2008-06-11
Brief Title:
Safety and Immunogenicity of 3 Lots of GSK Biologicals HBV-MPL Vaccine and Engerix-B in Healthy Volunteers 15y
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Safety and Immunogenicity of 3 Lots of GSK Biologicals Novel Adjuvanted Hepatitis B Vaccine Administered According to a 2 Dose Schedule and Engerix-B Administered According to a 3 Dose Schedule to Healthy Volunteers 15 Years of Age
Status:
COMPLETED
Status Verified Date:
2008-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was conducted to evaluate the lot-to-lot consistency of three lots of HBV-MPL vaccine and to compare their safety and immunogenicity with that of Engerix-B
Detailed Description:
At the time of conduct of this study the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None